We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Danaher Corp (DHR) Common Stock USD0.01

Sell:$265.86 Buy:$265.91 Change: $3.01 (1.14%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
Change: $3.01 (1.14%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
Change: $3.01 (1.14%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

Contact details

2200 Pennsylvania Ave NW Ste 800W
United States
+1 (202) 8280850

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$195.67 billion
Shares in issue:
724.00 million
Life Sciences Tools & Services
New York Stock Exchange
United States
US dollar

Key personnel

  • Steven Rales
    Chairman of the Board
  • Rainer Blair
    President, Chief Executive Officer, Director
  • Matthew McGrew
    Chief Financial Officer, Executive Vice President
  • Christopher Riley
    Executive Vice President
  • Julie Sawyer Montgomery
    Executive Vice President - Diagnostics
  • Jose-Carlos Gutierrez-Ramos
    Senior Vice President, Chief Science Officer
  • Brian Ellis
    Senior Vice President, General Counsel
  • Georgeann Couchara
    Senior Vice President - Human Resources
  • William King
    Senior Vice President - Strategic Development
  • Daniel Raskas
    Senior Vice President - Corporate Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.